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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) and asthma are common chronic diseases that are
frequently accompanied by depression and/or anxiety. However, symptoms of depression and anxiety are often
not recognized and therefore not treated. Currently, only a few studies have tested new clinical approaches that
could improve the treatment of co-morbid depression and anxiety in these groups of patients.
Methods/design: The present randomized controlled study will be conducted within the framework of PoZoB
(Praktijk Ondersteuning Zuid-Oost Brabant), a large primary care organization in the Netherlands. Patients with
asthma/COPD and co-morbid anxiety/depression will be included in order to test the effectiveness of a disease
management approach to treat these co-morbid disorders. Important elements of this approach are: 1) systematic
screening to improve detection of anxiety and depression 2) treatment in case of positive screening 3) monitoring
of anxiety and depression 4) intensified treatment in case of non-remission (stepped care).
Discussion: The present study is a large primary care study on the treatment of co-morbid depression and anxiety
in patients with asthma and COPD. Strengths of this study are its randomized design, the focus on implementation
in primary care and the fact that it applies the latest findings on the treatment of depression and anxiety. First
results are expected in 2012/2013.
Trial registration: Netherlands Trial Register (NTR): NTR2626
Keywords: Asthma, Chronic Obstructive Pulmonary Disease, Anxiety, Depression, Collaborative Care, Disease Man-
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Background
Chronic Obstructive Pulmonary Disease (COPD) and
asthma are common chronic diseases, with a worldwide
prevalence of around 9 to 10% [1] for COPD and 1 to
18% for asthma [2]. Although they represent two dis-
tinct entities, the disease processes and physical symp-
toms of both diseases overlap and can provoke a
considerable burden on the daily lives of affected
patients. The impact of these chronic conditions how-
ever, is not only characterized by a substantial physical
burden, but also by the frequent occurrence of co-mor-
bid affective problems like depression or anxiety [3].
Depression and Anxiety in Asthma and COPD
The prevalence of depression and anxiety in patients
with COPD varies widely between studies [4-6]. Recently
Zhang et al. did a systematic review, meta-analysis and
meta-regression on the prevalence of depressive symp-
toms in patients with COPD; only studies including a
healthy control group were eligible. They found that
patients with COPD have a higher prevalence of depres-
sive symptoms than healthy controls (24,6%, 95% CI:
20.0 - 28.6% vs. 11,7%, 95% CI: 9-15.1%) [7]. For anxiety
such a meta-analysis has not been conducted yet,
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however there is a review by Yohannes et al. on depres-
sion and anxiety in chronic heart failure and COPD. In
their review Yohannes et al. report rates between 6 and
74% for self-reported symptoms of anxiety [5]. In
asthma there is less variation in the prevalence rates for
depression (around 10%) and anxiety (between 12 to 50)
[8,9].
Asthma and COPD patients with co-morbid depres-
sion and/or anxiety tend to report an overall worse
health status [5,10]. In addition, prospective research in
patients with COPD showed that higher depression
scores were associated with higher exacerbation fre-
quencies (for symptom-based exacerbations: adjusted
IRR, 1.51; 95% CI, 1.01-2.24; for event-based exacerba-
tions: adjusted IRR, 1.56; 95% CI, 1.02-2.40) [10], a
higher risk of hospitalization during follow-up (adjusted
IRR, 1.72; 95% CI, 1.04-2.85) [10] and higher mortality
rates (hazard ratio, 1.93; 95% CI, 1.04-3.58 and OR,
2.74; 95% CI, 1.42-5.29, respectively) [11,12] while anxi-
ety was associated with increased overall length of
exacerbations (1.92 times longer CI, 1.04-3.54) [10].
Moreover, anxiety and depression may even be more
decisive predictors of functional capacity in patients
with COPD than physiological markers such as lung
function (OR 1.13; 95% CI, 1.02-1.26; versus no signifi-
cant result for FEV1) [13].
In asthma, depression appeared to be associated with
less adequate medication use and a lower level of physi-
cal exercise [8,9,14], and anxiety with more asthma
symptoms, higher medication use and a more frequent
use of healthcare services [15]. The latter, in turn, might
explain the negative association that has been reported
between anxiety and inflammation of the airways. Anxi-
ety, as suggested, might lead to more prescription and/
or greater consumption of corticosteroids which might
result in less inflammation of the airways [9,15-17].
Hence, co-morbid depression and anxiety in patients
with asthma or COPD not only affect quality of life but
also treatment outcomes. In clinical practice however,
there is a considerable under-detection of anxiety and
depression; less than half of the depressed and/or
anxious patients are recognized [18]. In patients with
respiratory illnesses, recognizing depression or anxiety is
further complicated due to overlap in symptoms, which
makes a differential diagnosis difficult [19] and results
in inadequate treatment of co-morbid depression and
anxiety.
Only a few studies have examined how these co-mor-
bid disorders should preferentially be treated [6,20-23].
Most studies were conducted within secondary care set-
tings and investigated the short-term effectiveness of
one type of behavioral therapy (e.g. education, cognitive
behavioral therapy (CBT), problem solving therapy
(PST), or relaxation therapy) without monitoring of long
term results [6,20,21]. A large primary care study on
late life depression in a general population, however,
showed that a collaborative care approach in which
mood status is monitored, with subsequent intensifica-
tion of treatment when necessary was more effective in
treating depression than merely offering one type of
treatment [24].
The present study
These findings resulted in the establishment of the
‘DiMaCoDeA-AC’ study; a study on a Disease Manage-
ment approach for Co-morbid Depression and Anxiety
in primary care patients with asthma or COPD. Employ-
ing a randomized controlled trial design, the effective-
ness of a newly developed disease management
approach is tested. In order to investigate the effective-
ness of this new approach for the treatment of depres-
sion and anxiety in patients with asthma or COPD, it is
compared to usual asthma/COPD care (care as usual).
The disease management approach contains four core
elements: 1) systematic screening to improve detection
of anxiety and depression 2) treatment in case of posi-
tive screening 3) monitoring of anxiety and depression
and 4) intensified treatment in case of non-remission
(stepped care). The study will last for two years, in
which treatment is offered during the first year, the sec-
ond year will function as follow-up to study long-term
effects. To the best of our knowledge such an approach
has not been studied yet in these patient populations in
a primary care setting.
Methods/Design
Hypotheses
Based on the current literature, we hypothesize that a
disease management approach will result in reduced
symptoms of depression and anxiety, reduced disease
specific distress, and improved lifestyle behaviors (e.g.
smoking cessation, increased physical activity, better
medication adherence) and quality of life when com-
pared to care as usual.
Setting
The study will be conducted in collaboration with
PoZoB (Praktijk ondersteuning Zuid-oost Brabant), a
large managed care organization in the south of the
Netherlands, established in 2001. PoZoB supports
approximately 200 general practitioners (GPs) in regu-
lating the care of patients with a chronic disease in a
structured, optimal manner. In order to achieve this,
several disease specific management programs have
been developed. The first program ‘DiaZoB’ started in
2005 and regulates the care of patients with type 2 dia-
betes mellitus [25,26]. Following the success of DiaZoB,
the ‘AsCoZoB’ management program was initiated in
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2008 to regulate the care for patients with asthma and/
or COPD and, during that same year, steps were taken
to develop a ‘care program’ that focuses on the mental
health domain. Recently, PoZoB developed a new man-
agement program for patients with cardiovascular risks
and heart failure, the ‘CVRM/HF’ management program.
These programs give the GP’s the opportunity to refer
patients with diabetes, asthma, COPD, cardiovascular
risks, heart failure and/or mild mental health problems
to special primary care nurses within their own general
practice.
Subjects
For the present study, only patients included in the
AsCoZoB management program are eligible for partici-
pation, further exclusion criteria are: age below 18, cur-
rently receiving treatment for depression and/or anxiety,
being diagnosed with a psychiatric disorder, suicidal
ideation and not being able to read or speak Dutch suf-
ficiently. All eligible patients will be approached via mail
and screened for depression and anxiety using valid and
reliable instruments. Patients with elevated scores on
these scales will be invited for a baseline interview to
further clarify possible exclusion criteria and to deter-
mine whether they suffer from a mood/anxiety disorder
or sub threshold depression/anxiety using the depression
and anxiety sections of the ‘Mini International Neurop-
sychiatric Interview’ (M.I.N.I.) [27]. Following this inter-
view, patients meeting inclusion criteria are further
informed about the design of the study and asked to
give written informed consent if willing to participate.
Informed consent will be sought for a) using anonymous
data from the questionnaires for reports and scientific
publications and b) for informing the general practi-
tioner about study results. After written informed con-
sent, patients will be included in the study and
randomized to either the disease management or the
care as usual condition.
Randomization
Randomization will be performed by an external agency
using a computerized random number generator. After
inclusion the interviewer will call the agency to open an
envelope which contains the condition to which the
patient is allocated. To obtain equal numbers in both
conditions a block randomization design is chosen.
Design
Intervention: Disease management for co-morbid anxiety
and depression
Within a week after the baseline interview, patients allo-
cated to the disease management condition will be
invited to start with a stepped care program consisting
of three consecutive steps and monitoring of results,
since anxiety and depression often are recurrent condi-
tions. The stepped care intervention starts with four ses-
sions of extensive psycho-education in which general
information on anxiety and/or depression (e.g. their pre-
valence and signals) and their relation to asthma or
COPD will be provided, supplemented with the rationale
of cognitive behavioral therapy and practical tools to
cope with symptoms of anxiety and/or depression. In
case of non-remission of symptoms, patients will enter
step two, consisting of a course on coping with depres-
sion and/or anxiety, depending on a patients need. Ear-
lier research has demonstrated that this type of
treatment is effective in reducing psychological distress
in patients with asthma or COPD [20,28-31]. The course
on anxiety was developed by the institute of mental
health and addiction (Trimbos) in the Netherlands and
has proven to be successful in reducing anxiety [32].
The course will be offered to individual patients and
consists of ten consultations of approximately 30 min-
utes. Main elements are cognitive restructuring through
the principals of cognitive behavioral therapy, behavioral
activation, social skills training, and relapse prevention
by discussing how to recognize and react on the first
symptoms of depression/anxiety [33]. In case of non-
remission of symptoms after step two, patients will
enter step three: coaching complemented with anti-
depressant and/or anxiolytic medication. Coaching
entails six booster sessions from the courses described
in step two. Medication is optional and will be pre-
scribed by the general practitioner in accordance with
the guidelines of the Dutch College of General Practi-
tioners (Nederlands Huisartsen Genootschap standaard).
Apart from the prescription of medication in step
three, all these steps will be performed by trained pri-
mary care nurses. A schematic outline of the stepped
care program is presented in Figure 1.
After each step (non-) remission is determined by
monitoring of results using validated questionnaires.
When further treatment is not indicated the emotional
well-being of patients is monitored every three months
for one year (using the PHQ-9 and the GAD-7). Patients
are offered a next step in case of recurrent symptoms of
anxiety or depression.
Care as usual
Within the care as usual condition no extra interven-
tions are offered. Patients receive care as defined in the
AsCoZoB management program (two annual visits with
the primary care nurse to monitor disease progression),
supplemented with a set of questionnaires including the
PHQ-9 and GAD-7, every three months to record their
psychological symptoms. Only if two consecutive scores
on these questionnaires are equal to or above 15, or
when scores indicate possible suicidal ideation, the GP
is informed. However, patients can always consult their
Pommer et al. Trials 2012, 13:6
http://www.trialsjournal.com/content/13/1/6
Page 3 of 7
GP when necessary and receive treatment for depres-
sion/anxiety by the GP, or (after a referral) by a mental
health specialist.
Measurements
Both patients in the disease management and the care as
usual condition will complete a set of questionnaires on
seven occasions: T0 (baseline), T1 (3 months), T2 (6
months), T3 (9 months), T4 (12 months), T5 (18
months), T6 (24 months), of which T0, T4 and T6 will
be done through interviewing. The instruments will con-
sist of generic and asthma/COPD specific self-report
questionnaires; table 1 presents an overview of variables
measured at each time point. Moreover, at the baseline
assessment, questions regarding demographic variables
(e.g. age, marital status, work, educational level, socioe-
conomic status), psychiatric history (e.g. previous diag-
nosis of depression and/or anxiety, family history
regarding psychiatric diagnosis) and/or health behaviors,
(e.g. alcohol use, smoking habits, physical activity) will
also be included. Clinical variables (FEV1/FVC and




1. The Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a short self-report questionnaire that is
based on the nine symptoms of major depression as
defined in the Diagnostic and Statistical Manual (DSM-
IV). The PHQ-9 measures the presence of depressive
symptoms in the past two weeks with four response
options (’Not at all’, ‘Several days’, ‘More than half the
days’ and ‘Nearly every day’) and is often used in pri-
mary care settings. The scale has good overall accuracy,
sensitivity and specificity in a general primary care
population [34]. Lamers et al. recently did a study to
determine what cut-off point of the PHQ-9 gave best
sensitivity and specificity in patients with COPD, they
found a cut-off of seven can best be used to indicate
possible depression [35].
2. The Generalized Anxiety Disorder-7 scale (GAD-7)
The GAD-7 was originally developed to screen for gen-
eralized anxiety disorder in primary care patients, how-
ever the scale has also shown good reliability and
validity to detect other anxiety disorders [36]. The scale
consists of seven items that, just as the items of the
PHQ-9, are based on the DSM-IV criteria, responses
range from ‘not at all’ to ‘nearly every day’. A score
above seven will be used to indicate a possible anxiety
disorder.
3. Mini International Neuropsychiatric Interview (M.I.N.
I.)
The M.I.N.I. is a short diagnostic interview, also based
on the DSM-IV criteria, that focuses on the existence of
current psychiatric disorders [37]. The interview consists
of separate modules to diagnose specific disorders. In
this study, only the modules ‘depression’ and ‘anxiety’
will be administered to be able to diagnose past and
current episodes.
Quality of life/Health Status
1. Clinical COPD Questionnaire (CCQ)
The CCQ is a valid and reliable disease specific self
administered questionnaire that measures “clinical con-
trol”, which is ‘the full range of clinical impairment that
patients with COPD may experience as a result of their
disease’ [38]; the questionnaire is often referred to as a
health status questionnaire. It was developed as a short
questionnaire for use in everyday clinical practice and
consists of 10 items, that can be answered on a seven
point scale ranging from ‘never’ to ‘almost all the time’
and ‘not limited at all’ to ‘totally limited/unable to do’
[38].
2. Asthma Control Questionnaire (ACQ)
The ACQ is a seven item, self administered, question-
naire developed to evaluate treatment effects by
Figure 1 Schematic outline of the stepped care program.
Table 1 variables measured at each time point
FEV1 PHQ-9 GAD-7 M.I.N.I. CCQ ACQ SF12
Time




T4 X X X X X X X
T5 X X
T6 X X X X X X X
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measuring asthma control, with good reliability and
validity. All questions have a unique response scale with
scores ranging from ‘zero’ to ‘six’, a high score always
indicates poor control [39].
3. Health Survey (SF-12)
The SF-12 is a health status questionnaire composed of
12 items which are derived from the ‘Health Survey 36’.
It has two components (mental and physical) that mea-
sure functional status, wellbeing and general health,
higher scores indicate a better health status [40]. The
scale was developed to use in a variety of chronic dis-
eases including asthma and COPD [41,42].
Ethical principles
The study will be conducted in accordance with the
principles described in the Helsinki Declaration and in
accordance with ‘The Medical Research Involving
Human Subjects Act’ (WMO) and is approved by the
medical ethics committee of the Elizabeth Hospital Til-
burg, the Netherlands NL33363.008.10.
Planned statistical analyses
Because it appears to be difficult to distinguish asthma
and COPD in clinical practice, the decision was made to
conduct the statistical analyses on the whole group of
participants. All the data will be analyzed with the latest
version of the ‘Statistical Package for Social Sciences’
(SPSS) and according to the intention-to-treat principle.
First prevalence of depression and anxiety will be dis-
played in frequency tables and both conditions (control
and intervention) will be compared using the Chi-square
(Fisher’s exact tests when appropriate) and Student’s t-
test, for discrete and continues variables respectively.
Thereafter the effect of the intervention will be deter-
mined using multilevel analyses (mixed effect regression
models) to compare baseline and follow up measures of
all continuous data (scores on the PHQ-9, GAD-7, SF-
12, CCQ and ACQ). In all these analyses a ‘p-value’ of
less than 0.05 will be considered statistically significant.
Sample size calculation
In this study the change in scores on the PHQ-9 and
GAD-7 are chosen as primary outcome measures to
determine the effect of a disease management approach.
Therefore, when calculating the required sample size,
the desired difference in scores between the intervention
and control condition on these scales was considered as
starting point. A difference of 0.5 standard deviations
was regarded necessary to find a clinically significant
effect of the intervention. In order to detect this differ-
ence and assuming a power of 80% a minimum of 64
patients is needed in each condition [43]. When assum-
ing that 20% of the participants drop-out, a number
considered normal in this type of research, a minimum
of 80 patients per condition is needed to maintain suffi-
cient power. We expected that in order to reach this
number, while anticipating a response-rate of 70% of
which 20% is eligible, a total of 1142 patients will need
to be screened.
Discussion
This article describes the background, objectives and
design of a large randomized controlled trial that will
test the effectiveness of a stepped care program to treat
co-morbid depression and anxiety in patients with
asthma and/or COPD. Previous research in asthma and
COPD has already shown that depression and anxiety
are common co-morbidities in these patient populations
and are negatively associated with functional capacity,
health status, and health behaviors such as physical
activity and positively with use of healthcare services,
and health care costs [5,6,8-12,14-17]. However, rando-
mized studies on the effects of treating depression and
anxiety are scarce, mostly conducted in secondary care
and often focusing on the effects of one type of therapy.
Therefore, this study was developed to test the effective-
ness of a disease management approach for co-morbid
depression and anxiety in these patient populations.
Important elements of this approach are: 1) systematic
screening to improve detection of anxiety and depres-
sion using validated screening tools since symptoms of
depression and anxiety are often not recognized and
therefore remain untreated [18] 2) treatment in case of
positive screening 3) monitoring of anxiety and depres-
sion and 4) intensified treatment in case of non-remis-
sion (stepped care). Other strengths of DiMaCoDeA-AC
include the large sample size and its implementation in
clinical practice to determine its effectiveness. However,
the design of the study also has some limitations.
Because the study will be conducted in practices of GP’s
who are already involved in a mental health program,
there is a chance that the usual care is already relatively
well organized with respect to co-morbid depression
and/or anxiety. Another limitation is the choice to put
asthma and COPD together in the statistical analyses
since differentiating asthma and COPD often proves dif-
ficult in clinical practice. That does not mean however,
that there are no differences between patients with
asthma and COPD, patients with asthma, for example,
will, on average, be younger than patients with COPD.
Conclusions
In conclusion, asthma and COPD are both common
chronic diseases that may provoke a considerable bur-
den of disease, the current literature indicates that this
burden of disease is often further increased by co-mor-
bid anxiety and affective problems like depression. How-
ever, research into possible treatment strategies to
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alleviate this additional burden is limited. Previous
reports on treatment of depression and anxiety suggest
that a collaborative care approach may be the most ben-
eficial. Therefore, the DiMaCoDeA-AC study tests the
use of this approach to treat co-morbid depression and
anxiety in patients with asthma and COPD. First results
are expected in 2012/2013 and are expected to shed
more light on the effect of monitoring and treating
depression and anxiety in these patient populations.
Trial status
The DiMaCoDeA-AC trial was conceived and designed
in 2010. At the time this manuscript was submitted full
approval by the Medical Ethics Committee had been
obtained. The first participants were randomized in Jan-
uary 2011.
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